• M Mirzababaee, B Shafiei, S Seifollahi, M Motazdian, L Fatholahi, S Delavari, R Naghshine, N Baharfar, F Tabeie, H Javadi, M Assadi, and I N Asli.
• Majid Assadi, MD, The Persian Gulf Nuclear Medicine Research Center, University of Medical Sciences, Bushehr 3631, Iran, Tel. +98/771/258 01 69, Fax +98/771/254 18 28.
• Nuklearmed Nucl Med. 2014 Jan 1;53(5):186-9.

ObjectiveTo compare safety and efficacy of pantoprazol , metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients.DesignFour-armed, parallel group, single blind, randomized controlled clinical trial, setting: A university hospital, registration: database for clinical trials IRCT2013061713705N1.Patients85 patients with differentiated thyroid cancer who received 131I.Main Outcome MeasuresPostradioiodine nausea and vomiting within three days of therapy (primary endpoint); occurrence of adverse reaction.ResultsThe patients' characteristics were similar within the study groups. Among the study variables, age, sex, administered dosage, history of previous GI complaints, and history of hyperemesis gravidarum in female patients were not statistically different among the groups (p > 0.05). The results revealed that only ondansetron shows a therapeutic benefit over the placebo in controlling nausea (p < 0.05); however, it does not prevent vomiting (p > 0.05). The other two drugs, pantoprazole and metoclopramide, did not control nausea (p > 0.05) or vomiting (p > 0.05).ConclusionsThis study may demonstrate that the therapeutic dose of ondansetron could be an effective prophylactic agent in controlling GI complaints in differential thyroid carcinoma (DTC) patients following RAI therapy; however, these preliminary findings should be validated in larger studies.

32 keywords...

hide…